---
layout: default
title: Transition Period
---

# Transition Periods and Regulatory Pathway Selection
The transitional periods defined by the MDR govern the placement, availability, and use of medical devices already on the market before the MDR's full implementation. These periods depend on the device class, certificates' validity, and specific regulatory requirements. 


## Table of Contents
- [Scope](#scope)
  - [New Products](#new-products)
  - [Legacy Devices](#legacy-devices-devices-already-on-the-market-under-mddaimdd)
- [Key Conditions and Timelines](#key-conditions-and-timelines)
  - [Placement on the Market](#placement-on-the-market)
  - [Availability and Use](#availability-and-use)
- [Key Requirements During the Transitional Period](#key-requirements-during-the-transitional-period)
  - [Post-Market Surveillance (PMS) and Vigilance](#post-market-surveillance-pms-and-vigilance)
  - [Quality Management System (QMS)](#quality-management-system-qms)
  - [Unique Device Identification (UDI)](#unique-device-identification-udi)
- [Special Cases](#special-cases)
  - [Well-Established Technologies](#well-established-technologies)
  - [Custom-Made Class III Implantable Devices](#custom-made-class-iii-implantable-devices)
- [Additional Resources](#additional-resources)
<br><br>

---

# Scope

## New Products

- **Direct compliance with MDR is required** without transitional periods.

## Legacy Devices (devices already on the market under MDD/AIMDD)

- **Transitional rules apply** if the device holds a valid certificate issued before **May 26, 2021**.
- These rules are critical for ensuring **continued availability** while adapting to MDR.

<br><br>

---
# Key Conditions and Timelines

## Placement on the Market

Legacy devices can remain on the market if:

- The certificate was **valid as of May 26, 2021**, and has not expired.
- **No significant changes** in design or intended purpose have occurred.
- A **conformity assessment application under MDR** is submitted by **May 26, 2024**.

### Specific Timelines:

- **Class III and implantable Class IIb:** Placement allowed until **December 31, 2027**.
- **Other Class IIb, Class IIa, and Is/Im:** Placement allowed until **December 31, 2028** *(TBD â€“ check for citation).*

### Availability and Use

- **As of February 2023**, there are no restrictions on the **continued availability** or **use of products** already on the market.

<br><br>

---
# Key Requirements During the Transitional Period

## Post-Market Surveillance (PMS) and Vigilance
- **Full compliance with MDR** is required from **May 26, 2021**, onward, even for legacy devices.

## Quality Management System (QMS)
- **MDR-compliant QMS** must be in place by **May 26, 2024** (**Article 10(9)**).

## Unique Device Identification (UDI)
- **Class III:** Required from **May 26, 2021**.
- **Class IIa/IIb:** Required from **May 26, 2023**.
- **Class I:** Required from **May 26, 2025**.

<br><br>

---
# Special Cases

## Well-Established Technologies
- Certain products *(e.g., sutures, staples)* have **specific exemptions** and may benefit from **extended timelines**.

## Custom-Made Class III Implantable Devices
- Eligible for **placement without an MDR QMS certificate** until **May 26, 2026**, provided certain conditions are met.

<br><br>

---
# Additional Resources

ðŸ“„ The **European Commission Q&A on MDR amendments** (**Regulation 2023/607**) provides additional information.  
ðŸ”— [**Access the document here**](https://health.ec.europa.eu/latest-updates/qa-practical-aspects-related-implementation-regulation-eu-2023607-extension-mdr-transitional-period-2023-03-28_en).
